BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

StemEx: Phase II/III data

The open-label, international Phase II/III ExCell trial in 101 patients with hematologic malignancies following myleoablative therapy who did not have a matched, family-related bone marrow donor showed that StemEx met the primary endpoint of improving the mortality rate at 100 days post-transplantation vs. a historical control group (15.8% vs. 24.5%, p=0.034). The historical control comprised a similar group of patients who...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >